Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease

results from a prospective multicentre patient-based survey*

Rahul Kalla, Ray Boyapati, Simen Vatn, Gonzalo Hijos, Benjamin Crooks, Gregory Thomas Moore, Veronica Hall, George Lipscomb, Fernando Gomollón, Jørgen Jahnsen, Salil Singh

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Introduction: Despite its success, there appears to be practical issues with Faecal Calprotectin (FC) testing in Inflammatory Bowel Diseases (IBD), including sample collection, delivery and processing delays. Patients’ perception and barriers to FC testing are yet to be explored in clinical practice. Method: A prospective patient survey was undertaken at IBD units in UK, Europe and Australia. A 9-point patient-based questionnaire was completed in clinic and included demographics, previous FC testing and FC sample difficulty rating score. Predictors of testing difficulty were derived using multivariable logistic regression analysis. Results: A total of 585 patients with IBD completed the survey; 306 males with a median age of 43 years (IQR: 31–54). There were 446 patients (76%) who had prior FC testing experience. Of these, 37% (n = 165) rated FC testing difficult; ‘sample collection’ (n = 106; 67%) being the most common reason reported. Multivariable regression analysis identified age <49 years (odds ratio (OR): 2.5, CI:1.6-4.0), disease duration <35 months (OR 1.4, CI:0.9–2.1) and testing location (UK centre: OR 1.9, CI:1.2-3.1) as predictors of a difficult FC rating score. Conclusions: A total of 37% of patients find FC testing challenging, in particular those aged <49 years, disease duration <35 months. Further studies understanding and addressing these practical issues may aid higher FC uptake in clinic.

Original languageEnglish
Pages (from-to)1437-1442
Number of pages6
JournalScandinavian Journal of Gastroenterology
Volume53
Issue number12
DOIs
Publication statusPublished - Dec 2018
Externally publishedYes

Keywords

  • biomarkers
  • compliance
  • Crohn’s disease
  • Faecal calprotectin
  • inflammatory bowel disease
  • survey
  • ulcerative colitis

Cite this

Kalla, Rahul ; Boyapati, Ray ; Vatn, Simen ; Hijos, Gonzalo ; Crooks, Benjamin ; Moore, Gregory Thomas ; Hall, Veronica ; Lipscomb, George ; Gomollón, Fernando ; Jahnsen, Jørgen ; Singh, Salil. / Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease : results from a prospective multicentre patient-based survey*. In: Scandinavian Journal of Gastroenterology. 2018 ; Vol. 53, No. 12. pp. 1437-1442.
@article{aca19895360548d5aa719df8ce2d2975,
title = "Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey*",
abstract = "Introduction: Despite its success, there appears to be practical issues with Faecal Calprotectin (FC) testing in Inflammatory Bowel Diseases (IBD), including sample collection, delivery and processing delays. Patients’ perception and barriers to FC testing are yet to be explored in clinical practice. Method: A prospective patient survey was undertaken at IBD units in UK, Europe and Australia. A 9-point patient-based questionnaire was completed in clinic and included demographics, previous FC testing and FC sample difficulty rating score. Predictors of testing difficulty were derived using multivariable logistic regression analysis. Results: A total of 585 patients with IBD completed the survey; 306 males with a median age of 43 years (IQR: 31–54). There were 446 patients (76{\%}) who had prior FC testing experience. Of these, 37{\%} (n = 165) rated FC testing difficult; ‘sample collection’ (n = 106; 67{\%}) being the most common reason reported. Multivariable regression analysis identified age <49 years (odds ratio (OR): 2.5, CI:1.6-4.0), disease duration <35 months (OR 1.4, CI:0.9–2.1) and testing location (UK centre: OR 1.9, CI:1.2-3.1) as predictors of a difficult FC rating score. Conclusions: A total of 37{\%} of patients find FC testing challenging, in particular those aged <49 years, disease duration <35 months. Further studies understanding and addressing these practical issues may aid higher FC uptake in clinic.",
keywords = "biomarkers, compliance, Crohn’s disease, Faecal calprotectin, inflammatory bowel disease, survey, ulcerative colitis",
author = "Rahul Kalla and Ray Boyapati and Simen Vatn and Gonzalo Hijos and Benjamin Crooks and Moore, {Gregory Thomas} and Veronica Hall and George Lipscomb and Fernando Gomoll{\'o}n and J{\o}rgen Jahnsen and Salil Singh",
year = "2018",
month = "12",
doi = "10.1080/00365521.2018.1527394",
language = "English",
volume = "53",
pages = "1437--1442",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa UK Ltd",
number = "12",

}

Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease : results from a prospective multicentre patient-based survey*. / Kalla, Rahul; Boyapati, Ray; Vatn, Simen; Hijos, Gonzalo; Crooks, Benjamin; Moore, Gregory Thomas; Hall, Veronica; Lipscomb, George; Gomollón, Fernando; Jahnsen, Jørgen; Singh, Salil.

In: Scandinavian Journal of Gastroenterology, Vol. 53, No. 12, 12.2018, p. 1437-1442.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease

T2 - results from a prospective multicentre patient-based survey*

AU - Kalla, Rahul

AU - Boyapati, Ray

AU - Vatn, Simen

AU - Hijos, Gonzalo

AU - Crooks, Benjamin

AU - Moore, Gregory Thomas

AU - Hall, Veronica

AU - Lipscomb, George

AU - Gomollón, Fernando

AU - Jahnsen, Jørgen

AU - Singh, Salil

PY - 2018/12

Y1 - 2018/12

N2 - Introduction: Despite its success, there appears to be practical issues with Faecal Calprotectin (FC) testing in Inflammatory Bowel Diseases (IBD), including sample collection, delivery and processing delays. Patients’ perception and barriers to FC testing are yet to be explored in clinical practice. Method: A prospective patient survey was undertaken at IBD units in UK, Europe and Australia. A 9-point patient-based questionnaire was completed in clinic and included demographics, previous FC testing and FC sample difficulty rating score. Predictors of testing difficulty were derived using multivariable logistic regression analysis. Results: A total of 585 patients with IBD completed the survey; 306 males with a median age of 43 years (IQR: 31–54). There were 446 patients (76%) who had prior FC testing experience. Of these, 37% (n = 165) rated FC testing difficult; ‘sample collection’ (n = 106; 67%) being the most common reason reported. Multivariable regression analysis identified age <49 years (odds ratio (OR): 2.5, CI:1.6-4.0), disease duration <35 months (OR 1.4, CI:0.9–2.1) and testing location (UK centre: OR 1.9, CI:1.2-3.1) as predictors of a difficult FC rating score. Conclusions: A total of 37% of patients find FC testing challenging, in particular those aged <49 years, disease duration <35 months. Further studies understanding and addressing these practical issues may aid higher FC uptake in clinic.

AB - Introduction: Despite its success, there appears to be practical issues with Faecal Calprotectin (FC) testing in Inflammatory Bowel Diseases (IBD), including sample collection, delivery and processing delays. Patients’ perception and barriers to FC testing are yet to be explored in clinical practice. Method: A prospective patient survey was undertaken at IBD units in UK, Europe and Australia. A 9-point patient-based questionnaire was completed in clinic and included demographics, previous FC testing and FC sample difficulty rating score. Predictors of testing difficulty were derived using multivariable logistic regression analysis. Results: A total of 585 patients with IBD completed the survey; 306 males with a median age of 43 years (IQR: 31–54). There were 446 patients (76%) who had prior FC testing experience. Of these, 37% (n = 165) rated FC testing difficult; ‘sample collection’ (n = 106; 67%) being the most common reason reported. Multivariable regression analysis identified age <49 years (odds ratio (OR): 2.5, CI:1.6-4.0), disease duration <35 months (OR 1.4, CI:0.9–2.1) and testing location (UK centre: OR 1.9, CI:1.2-3.1) as predictors of a difficult FC rating score. Conclusions: A total of 37% of patients find FC testing challenging, in particular those aged <49 years, disease duration <35 months. Further studies understanding and addressing these practical issues may aid higher FC uptake in clinic.

KW - biomarkers

KW - compliance

KW - Crohn’s disease

KW - Faecal calprotectin

KW - inflammatory bowel disease

KW - survey

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85057298192&partnerID=8YFLogxK

U2 - 10.1080/00365521.2018.1527394

DO - 10.1080/00365521.2018.1527394

M3 - Article

VL - 53

SP - 1437

EP - 1442

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 12

ER -